Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Xinmin ZhaoXin ZhangHanLin ChenHairong BaoXianghua WuHuijie WangHua BaoJiaohui PangSha WangJialei WangPublished in: Clinical chemistry (2024)
This study provided a comprehensive portrait of TKI-resistance mechanisms in ROS1+ NSCLC patients. Using in silico simulations of TKI activity, novel secondary mutations that may confer TKI resistance were identified and may support clinical therapeutic decision-making.
Keyphrases
- advanced non small cell lung cancer
- tyrosine kinase
- chronic myeloid leukemia
- end stage renal disease
- decision making
- epidermal growth factor receptor
- cell death
- dna damage
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- reactive oxygen species
- single cell
- stem cells
- molecular dynamics
- cell therapy
- molecular docking
- patient reported outcomes
- molecular dynamics simulations
- monte carlo